Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Receivables (2016 - 2025)

Historic Receivables for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $10.7 billion.

  • Gsk's Receivables rose 1161.98% to $10.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 billion, marking a year-over-year increase of 1161.98%. This contributed to the annual value of $9.8 billion for FY2024, which is 621.49% down from last year.
  • As of Q3 2025, Gsk's Receivables stood at $10.7 billion, which was up 1161.98% from $9.8 billion recorded in Q2 2025.
  • Gsk's Receivables' 5-year high stood at $18.4 billion during Q1 2022, with a 5-year trough of $8.1 billion in Q2 2022.
  • Over the past 5 years, Gsk's median Receivables value was $9.6 billion (recorded in 2021), while the average stood at $10.1 billion.
  • As far as peak fluctuations go, Gsk's Receivables soared by 10602.8% in 2022, and later crashed by 5496.75% in 2023.
  • Over the past 5 years, Gsk's Receivables (Quarter) stood at $12.3 billion in 2021, then fell by 21.06% to $9.7 billion in 2022, then grew by 7.75% to $10.5 billion in 2023, then fell by 5.63% to $9.9 billion in 2024, then rose by 8.44% to $10.7 billion in 2025.
  • Its Receivables stands at $10.7 billion for Q3 2025, versus $9.8 billion for Q2 2025 and $8.9 billion for Q1 2025.